» Articles » PMID: 33507893

Impact of COVID-19 on Cervical Cancer Screening Rates Among Women Aged 21-65 Years in a Large Integrated Health Care System - Southern California, January 1-September 30, 2019, and January 1-September 30, 2020

Overview
Date 2021 Jan 28
PMID 33507893
Citations 76
Authors
Affiliations
Soon will be listed here.
Abstract

On March 19, 2020, the governor of California issued a statewide stay-at-home order to contain the spread of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19).* The order reduced accessibility to and patient attendance at outpatient medical visits, including preventive services such as cervical cancer screening. In-person clinic visits increased when California reopened essential businesses on June 12, 2020. Electronic medical records of approximately 1.5 million women served by Kaiser Permanente Southern California (KPSC), a large integrated health care system, were examined to assess cervical cancer screening rates before, during, and after the stay-at-home order. KPSC policy is to screen women aged 21-29 years every 3 years with cervical cytology alone (Papanicolaou [Pap] test); those aged 30-65 years were screened every 5 years with human papillomavirus (HPV) testing and cytology (cotesting) through July 15, 2020, and after July 15, 2020, with HPV testing alone, consistent with the latest recommendations from U.S. Preventive Services Task Force. Compared with the 2019 baseline, cervical cancer screening rates decreased substantially during the stay-at-home order. Among women aged 21-29 years, cervical cytology screening rates per 100 person-months declined 78%. Among women aged 30-65 years, HPV test screening rates per 100 person-months decreased 82%. After the stay-at-home order was lifted, screening rates returned to near baseline, which might have been aided by aspects of KPSC's integrated, organized screening program (e.g., reminder systems and tracking persons lost to follow-up). As the pandemic continues, groups at higher risk for developing cervical cancers and precancers should be evaluated first. Ensuring that women receive preventive services, including cancer screening and appropriate follow-up in a safe and timely manner, remains important.

Citing Articles

The Association of the COVID-19 Pandemic with the Uptake of Colorectal Cancer Screening Varies by Socioeconomic Status in Flanders, Belgium.

Zheng S, Ding L, Greuter M, Tran T, Sidorenkov G, Hoeck S Cancers (Basel). 2024; 16(23).

PMID: 39682170 PMC: 11640482. DOI: 10.3390/cancers16233983.


Breast cancer and cervical cancer: a comparison of the period before and during the COVID-19 pandemic.

Stevanato K, Dos Santos L, Pelloso F, Pelloso Borghesan D, Consolaro M, de Almeida R BMC Womens Health. 2024; 24(1):485.

PMID: 39227848 PMC: 11370265. DOI: 10.1186/s12905-024-03325-3.


Barriers to Cervical Cancer Screening: A Systematic Review.

Farajimakin O Cureus. 2024; 16(7):e65555.

PMID: 39192892 PMC: 11347962. DOI: 10.7759/cureus.65555.


Noteworthy impacts of COVID-19 pandemic on cancer screening: A systematic review.

Wang H, Yang M, Xiong W, Wang Q, Zheng B, Bai Y Fundam Res. 2024; 4(3):484-494.

PMID: 38933198 PMC: 11197616. DOI: 10.1016/j.fmre.2023.12.016.


Impact of SARS-CoV-2 Pandemic on the Diagnosis of Cervical Cancer and Precursor Lesions-A Single-Center Retrospective Study.

Balan L, Secosan C, Sorop V, Pirtea M, Cimpean A, Chiriac D Medicina (Kaunas). 2024; 60(6).

PMID: 38929526 PMC: 11206154. DOI: 10.3390/medicina60060909.


References
1.
Arbyn M, Smith S, Temin S, Sultana F, Castle P . Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses. BMJ. 2018; 363:k4823. PMC: 6278587. DOI: 10.1136/bmj.k4823. View

2.
Carethers J, Sengupta R, Blakey R, Ribas A, DSouza G . Disparities in Cancer Prevention in the COVID-19 Era. Cancer Prev Res (Phila). 2020; 13(11):893-896. PMC: 8212395. DOI: 10.1158/1940-6207.CAPR-20-0447. View

3.
Abdel-Rahman O . Patient-related barriers to some virtual healthcare services among cancer patients in the USA: a population-based study. J Comp Eff Res. 2021; 10(2):119-126. DOI: 10.2217/cer-2020-0187. View

4.
Kaufman H, Chen Z, Niles J, Fesko Y . Changes in the Number of US Patients With Newly Identified Cancer Before and During the Coronavirus Disease 2019 (COVID-19) Pandemic. JAMA Netw Open. 2020; 3(8):e2017267. PMC: 7403918. DOI: 10.1001/jamanetworkopen.2020.17267. View

5.
Castanon A, Rebolj M, Pesola F, Sasieni P . Recovery strategies following COVID-19 disruption to cervical cancer screening and their impact on excess diagnoses. Br J Cancer. 2021; 124(8):1361-1365. PMC: 8039040. DOI: 10.1038/s41416-021-01275-3. View